This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
GNL3 · Western blot design guide
GNL3 Western Blot Planning Guide
Plan a GNL3 Western blot around the catalog-observed 62 kDa band, image-backed A03283-3 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
GNL3 Western Blot Experimental Design Guide
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 62 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 12-15% | |
| Positive control | Breast | |
| Negative control | Target knockdown/knockout |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 62 kDa |
| ⓘ | Localization | Nucleus / Nucleus, nucleolus |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human / Mouse / Rat |
Section 1
Real Curated GNL3 Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Adrenal gland |
| Gel % | 12-15% |
| Load | 20-30 µg total protein per lane |
| Transfer | Semi-dry, standard transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | A03283-3 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected GNL3 Western Blot Band Size?
Use the product-observed 62 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 62 kDa | Matches the authoritative product WB observation. |
| 62 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected GNL3 appearancePlan around 62 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 62 kDa; use this as the primary experimental expectation. |
| Calculated mass | 62 kDa from UniProt Q9BVP2; retain as context. |
| Gel selection | 12-15%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with A03283-3. |
| Situation | Likely cause | Next action |
|---|---|---|
| 62 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing GNL3 band
A03283-3 · GNL3
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for GNL3 Western blot
🧪Use Breast as the first positive-control candidate; no defensible HPA Not detected tissue was available, so use a target knockdown/knockout negative control.
Positive control: Breast (High)
Negative control: Target knockdown/knockout
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for GNL3
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Breast | Reported tissue cells | High | Protein (HPA) | HPA → |
| Adrenal gland | Reported tissue cells | High | Protein (HPA) | HPA → |
| Colon | Reported tissue cells | High | Protein (HPA) | HPA → |
| Cerebellum | Reported tissue cells | High | Protein (HPA) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|
Section 3
Advanced GNL3 Western Blot Tips
Deeper troubleshooting and optimisation questions for GNL3, answered from its protein features.
Which band should guide the blot?
Use 62 kDa, the observation attached to the authoritative A03283-3 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 62 kDa expectation.
Which positive control should I start with?
Start with Breast, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use a target knockdown/knockout control when no HPA Not detected tissue is available.
Which gel should I use?
Use 12-15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for GNL3 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should A03283-3 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents
GNL3 Western Blot Reagents
Human/Mouse/Rat-reactive GNL3 Western blot reagents with authoritative product imagery.
Real WB data
Anti-Nucleostemin/GNL3 Antibody Picoband®
Cat # A03283-3
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt Q9BVP2
- Human Protein Atlas — GNL3
- A03283-3 product record
- PMC13428458 — Enolase 2-mediated lactylation-dependent disruption of the GNL3-MDM2-p53 axis in age-related osteoarthritis (Cellular & molecular biology letters, 2026)
- PMC6421870 — The oncogenic role of GNL3 in the progression and metastasis of osteosarcoma (Cancer management and research, 2019)
- PMC5652940 — Upregulation of GNL3 expression promotes colon cancer cell proliferation, migration, invasion and epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway (Oncology reports, 2017)